BRIEF—Keytruda trial tests combo with antibody drug conjugate

Tokyo’s Daiichi Sankyo will participate in another Keytruda (pembrolizumab) combination trial with Merck & Co, adding to the some 150 studies the New Jersey, USA-based drugmaker is running featuring its blockbuster.

The Daiichi trial will evaluate a combination of the checkpoint inhibitor with the investigational HER2 targeting antibody drug conjugate DS-8201.

The combo is being tested against certain metastatic breast cancers and non-small cell lung cancers (NSCLC).